Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Males and females with histologically confirmed metastatic clear cell RCC * Measurable disease according to Response Criteria for Solid Tumors (RECIST) * No prior systemic cytotoxic chemotherapy * Subjects who have received either no prior therapy for RCC, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting VEGF or a VEGFR (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled * ECOG performance status of 0 or 1 * Life expectancy ≥3 months * Adequate organ and marrow function * No other malignancies within 5 years * Signed informed consent Exclusion Criteria: * Radiation to ≥25% of bone marrow within 30 days of XL999 treatment * Subjects who have received systemic anticancer therapy within 30 days of XL999 treatment * Subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered \>30 days prior to study enrollment * History of or known brain metastases, current spinal cord compression or carcinomatous meningitis * Uncontrolled and/or intercurrent illness * Pregnant or breastfeeding females * Known HIV